A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 3867-3874

  Felip, Enriqueta ^a   Rojo, Federico ^a   Reck, Martin ^b   Heller, Astrid ^c   Klughammer, Barbara ^d   Sala, Gemma ^a   Cedres, Susana ^a   Peralta, Sergio ^a   Maacke, Heiko ^d   Foernzler, Dorothee ^d   Parera, Marta ^a   Möcks, Joachim ^d   Saura, Cristina ^a   Gatzemeier, Ulrich ^b   Baselga, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Department of Thoracic Oncology ^*  (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; KI 67 ANTIGEN; LIVER ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; PLATINUM; PROTEIN KINASE B; PROTEIN P27; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; DIARRHEA; EGFR GENE; EYE TOXICITY; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RASH; RECEPTOR GENE; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; ADJUVANT CHEMOTHERAPY; DISEASE COURSE; DRUG EFFECT; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PROTO ONCOGENE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 52449101985     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5186     Document Type: Article

References (33)

1. Shepherd FA, Pereira JR, CiuleanuT, etal. Erlotinib in previously-treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
3. Paez JG, Jänne PA, Lee JC, Fernandez I, Llanes L, Berenguer A. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:497-500.
4. PaoW, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11.
5. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non- small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20.
6. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-92.
7. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55.
8. Hirsch FR.Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluoresecence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-45.
9. Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
10. Tsao MS, Kamel-Reid S, Shepherd FA. Assessing EGFR mutations. N Engl J Med 2006;354:527-8.
11. Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003;9:2478-86.
12. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histo-pathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.
13. Baselga J. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res 2003;9:2389-90.
14. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005;23: 5323-3.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985;53:457-81.
16. Laurent F, Montaudon M, LatrabeV, Bégueret H. Percutaneous biopsy in lung cancer. Eur J Radiol 2003;45:60-8.
17. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7 Suppl 4:31 -9.
18. Dancey JE. Predictive factors for epidermal growth factor receptor inhibitors-the bull's-eye hits the arrow. Cancer Cell 2004;5:411-5.
19. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ("Iressa", ZD1839) in non- small-cell lung cancer. Br J Cancer 2004;91:208-12.
20. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
21. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo- controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37
22. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24: 5034-42.
23. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-41.
24. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501.
25. Pao W, Miller VA. Epidermal growth factor mutations, small-molecule kinase inhibitors, and non- small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
26. Shigematsu H, Lin L.Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
27. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications of pharmacologic treatment. J Clin Oncol 2005;23:857-65.
28. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
29. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17
30. Eberhard OA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and combination with erlotinib. J Clin Oncol 2005;23:5900-9.
31. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358.774. an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 1997;57:4838-48
32. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006;20:1496-510.
33. Gong Y. Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PloS Med 2007;4:1655-68.